/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
PHILADELPHIA–(BUSINESS WIRE)–On April 26, 2019, Delaware Enhanced Global Dividend and Income Fund
(NYSE: DEX) (the “Fund”), a closed-end fund, paid a monthly distribution
on its common stock of $0.0904 per share to shareholders of record at
the close of business on April 18, 2019.
The following table sets forth the estimated amount of the sources of
distribution for purposes of Section 19 of the Investment Company Act of
1940, as amended, and the related rules adopted thereunder. The Fund
estimates the following percentages, of the total distribution amount
per share, attributable to (i) net investment income, (ii) net realized
short-term capital gain, (iii) net realized long-term capital gain and
(iv) return of capital or other capital source. These percentages are
disclosed for the current distribution as well as the fiscal
year-to-date cumulative distribution amount per share for the Fund.
| Current Distribution from: | ||||
|
Per Share ($) |
% |
|||
| Net Investment Income | 0.0406 | 44.9% | ||
| Net Realized Short-Term Capital Gain | 0.0000 | 0.0% | ||
| Net Realized Long-Term Capital Gain | 0.0000 | 0.0% | ||
| Return of Capital or other Capital Source |
0.0498 |
55.1% |
||
| Total (per common share) | 0.0904 | 100.00% | ||
| Fiscal Year-to-Date Cumulative | ||||
| Distributions from: | ||||
|
Per Share ($) |
% |
|||
| Net Investment Income | 0.1691 | 37.3% | ||
| Net Realized Short-Term Capital Gain | 0.0000 | 0.0% | ||
| Net Realized Long-Term Capital Gain | 0.0179 | 4.0% | ||
| Return of Capital or other Capital Source |
0.2659 |
58.7% |
||
| Total (per common share) | 0.4529 | 100.00% | ||
Shareholders should not draw any conclusions about the Fund’s
investment performance from the amount of this distribution or from the
terms of the Fund’s managed distribution policy. The amounts and sources
of distributions reported in this 19(a) Notice are only estimates and
are not being provided for tax reporting purposes. The actual amounts
and sources of the amounts for tax reporting purposes will depend upon
the Fund’s investment experience during the remainder of its fiscal year
and may be subject to changes based on tax regulations. The Fund will
send you a Form 1099-DIV for the calendar year that will tell you how to
report these distributions for federal income tax purposes.
Subject to the foregoing, the Fund estimates (as of the date hereof)
that it has distributed more than its income and net realized capital
gains for the fiscal year ending November 30, 2019; therefore, a portion
of your distribution may be a return of capital. A return of capital may
occur for example, when some or all of the money that you invested in
the Fund is paid back to you. A return of capital distribution does not
necessarily reflect the Fund’s investment performance and should not be
confused with ‘yield’ or ‘income.’
Presented below are return figures, based on the change in the Fund’s
Net Asset Value per share (“NAV”), compared to the annualized
distribution rate for this current distribution as a percentage of the
NAV on the last business day of the month prior to distribution record
date.
|
Fund Performance and Distribution Information |
||
| Fiscal Year to Date (12/01/2018 through 3/29/2019) | ||
| Annualized Distribution Rate as a Percentage of NAV^ | 9.83% | |
| Cumulative Distribution Rate on NAV^^ | 4.11% | |
| Cumulative Total Return on NAV* | 5.40% | |
|
Average Annual Total Return on NAV for the 5-Year Period Ending 3/29/19** |
3.88% | |
^ Based on the Fund’s NAV as of March 29, 2019.
^^ Cumulative distribution rate is the cumulative amount of
distributions paid during the Fund’s fiscal year ending November 30,
2019 based on the Fund’s NAV as of March 29, 2019.
*Cumulative fiscal year-to-date return is based on the change in NAV
including distributions paid and assuming reinvestment of these
distributions for the period December 1, 2018 through March 29, 2019.
**The 5-year average annual total return is based on change in NAV
including distributions paid and assuming reinvestment of these
distributions and is through the last business day of the month prior to
the month of the current distribution record date.
While the NAV performance may be indicative of the Fund’s investment
performance, it does not measure the value of a shareholder’s investment
in the Fund. The value of a shareholder’s investment in the Fund is
determined by the Fund’s market price, which is based on the supply and
demand for the Fund’s shares in the open market.
About DEX
The Fund’s primary investment objective is to seek current income, with
a secondary objective of capital appreciation. The Fund invests globally
in dividend-paying or income-generating securities across multiple asset
classes, including but not limited to: equity securities of large,
well-established companies; securities issued by real estate companies
(including real estate investment trusts and real estate industry
operating companies); debt securities (such as government bonds;
investment grade and high risk, high yield corporate bonds; and
convertible bonds); and emerging market securities. The Fund also uses
enhanced income strategies by engaging in dividend capture trading;
option overwriting; and realization of gains on the sale of securities,
dividend growth, and currency forwards. There is no assurance that the
Fund will achieve its investment objectives.
Under normal market conditions, the Fund will invest: (1) at most 60% of
its net assets in securities of U.S. issuers; and (2) at least 40% of
its net assets in securities of non-U.S. issuers, unless market
conditions are not deemed favorable by the Manager, in which case, the
Fund would invest at least 30% of its net assets in securities of
non-U.S. issuers; and (3) the Fund may invest up to 25% of its net
assets in securities issued by real estate companies (including real
estate investment trusts and real estate industry operating companies).
In addition, the Fund utilizes leveraging techniques in an attempt to
obtain higher return for the Fund.
The Fund has implemented a managed distribution policy. Under the
policy, the Fund is managed with a goal of generating as much of the
distribution as possible from net investment income and short-term
capital gains. The balance of the distribution will then come from
long-term capital gains to the extent permitted, and if necessary, a
return of capital. Even though the Fund may realize current year capital
gains, such gains may be offset, in whole or in part, by the Fund’s
capital loss carryovers from prior years.
Currently under the Fund’s managed distribution policy, the Fund makes
monthly distributions to common shareholders at a targeted annual
distribution rate of 10% of the Fund’s average net asset value (“NAV”)
per share. The Fund will calculate the average NAV per share from the
previous three full months immediately prior to the distribution based
on the number of business days in those three months on which the NAV is
calculated. The distribution will be calculated as 10% of the prior
three month’s average NAV per share, divided by 12. The Fund will
generally distribute amounts necessary to satisfy the Fund’s managed
distribution policy and the requirements prescribed by excise tax rules
and Subchapter M of the Internal Revenue Code. This distribution
methodology is intended to provide shareholders with a consistent, but
not guaranteed, income stream and a targeted annual distribution rate
and is intended to narrow the discount between the market price and the
NAV of the Fund’s common shares, but there is no assurance that the
policy will be successful in doing so. The methodology for determining
monthly distributions under the Fund’s managed distribution policy will
be reviewed at least annually by the Fund’s Board of Trustees, and the
Fund will continue to evaluate its distribution in light of ongoing
market conditions.
The payment of dividend distributions in accordance with the managed
distribution policy may result in a decrease in the Fund’s net assets. A
decrease in the Fund’s net assets may cause an increase in the Fund’s
annual operating expenses and a decrease in the Fund’s market price per
share to the extent the market price correlates closely to the Fund’s
net asset value per share. The managed distribution policy may also
negatively affect the Fund’s investment activities to the extent that
the Fund is required to hold larger cash positions than it typically
would hold or to the extent that the Fund must liquidate securities that
it would not have sold, for the purpose of paying the dividend
distribution. The managed distribution policy may, under certain
circumstances, cause the amounts of taxable distributions to exceed the
amount minimally required to be distributed under the tax rules, such
excess will be taxable as ordinary income to the extent loss carry
forwards reduce the required amount of capital gains distributions in
that year. Investors should consult their tax advisor regarding federal,
state, and local tax considerations that may be applicable in their
particular circumstances.
About Macquarie Investment Management
Macquarie Investment Management, a member of Macquarie Group, includes
the former Delaware Investments and is a global asset manager with
offices throughout the United States, Europe, Asia, and Australia. As
active managers, we prioritize autonomy and accountability at the team
level in pursuit of opportunities that matter for clients. Macquarie
Investment Management is supported by the resources of Macquarie Group
(ASX: MQG; ADR: MQBKY), a global provider of asset management,
investment, banking, financial and advisory services.
Advisory services are provided by Macquarie Investment Management
Business Trust, a registered investment advisor. Macquarie Group refers
to Macquarie Group Limited and its subsidiaries and affiliates
worldwide. For more information about Delaware Funds® by
Macquarie, visit delawarefunds.com or call 800 523-1918.
Other than Macquarie Bank Limited (MBL), none of the entities referred
to in this document are authorized deposit-taking institutions for the
purposes of the Banking Act 1959 (Commonwealth of Australia). The
obligations of these entities do not represent deposits or other
liabilities of MBL, a subsidiary of Macquarie Group Limited and an
affiliate of Macquarie Investment Management. MBL does not guarantee or
otherwise provide assurance in respect of the obligations of these
entities, unless noted otherwise.
© 2019 Macquarie Management Holdings, Inc.
Contacts
Investors
Computershare
866 437-0252
delawarefunds.com/closed-end
Media contacts
Daniela Palmieri
215 255-8878
Jessica Fitzgerald
215 255-1336
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom
NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”
The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.
Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html
-
Cannabis2 weeks ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
StickIt2 weeks agoStickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis2 weeks agoIM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks agoAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
Cannabis2 weeks ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
transfer7 days ago
IMC to transfer its Oranim Pharmacy shares back to the seller
